Tests blood microRNA markers to track immune response after heart transplant
Studies blood microRNA markers to predict rejection and infection in adults after heart transplant.
Plain-language title generated from the registry record
Registry title: OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
Key facts
- Where
- Boston, Charleston, Dallas, Los Angeles, Nashville, and Palo Alto, United StatesSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06939751, who can take part
Where in United States
- Tufts Medical CenterBoston, United StatesTaking people
- Medical University of South CarolinaCharleston, United StatesTaking people
- Baylor University Medical CenterDallas, United StatesTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesTaking people
- Vanderbilt UniversityNashville, United StatesTaking people
- Stanford UniversityPalo Alto, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwestern University
- Trial code
- NCT06939751
- Record updated
- 11 August 2026
- Original description
This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.Read full original descriptionShow less
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Inclusion: Age ≥ 18 years at enrollment; Receipt of orthotopic heart transplant (OHT) within the prior 1 month ± 2 weeks; Planned follow-up at the transplant center for a minimum of one-year; Patient able and willing to comply with the study visit schedule, study procedures, and study requirements.
Exclusion: Recipient of a multi-organ transplant; History of prior solid organ transplant before the index heart transplant; Ongoing mechanical circulatory support or hemodynamic instability (e.g., inotrope or vasopressor therapy); Ongoing need for renal replacement therapy and/or dialysis; Active infection requiring either a) hospitalization b) treatment with antimicrobial therapy or c) reduction in immunosuppression; Active rejection being treated with intravenous medications or plasmapheresis.